Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 347

1.

An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretroviral therapy.

Barbaro G, Di Lorenzo G, Cirelli A, Grisorio B, Lucchini A, Hazra C, Barbarini G.

Clin Ther. 2003 Sep;25(9):2405-18. Erratum in: Clin Ther. 2004 Jan;26(1):175.

PMID:
14604740
2.

Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.

Jones R, Sawleshwarkar S, Michailidis C, Jackson A, Mandalia S, Stebbing J, Bower M, Nelson M, Gazzard BG, Moyle GJ.

HIV Med. 2005 Nov;6(6):396-402.

3.

Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor.

Rakotoambinina B, Médioni J, Rabian C, Jubault V, Jais JP, Viard JP.

J Acquir Immune Defic Syndr. 2001 Aug 15;27(5):443-9.

PMID:
11511820
4.
5.

Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors.

Galli M, Ridolfo AL, Adorni F, Gervasoni C, Ravasio L, Corsico L, Gianelli E, Piazza M, Vaccarezza M, d'Arminio Monforte A, Moroni M.

J Acquir Immune Defic Syndr. 2002 Jan 1;29(1):21-31.

PMID:
11782586
6.
7.

Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in children vertically infected with HIV.

Palma P, Romiti ML, Cancrini C, Pensieroso S, Montesano C, Santucci MB, Bernardi S, Martino AM, Rossi P, Castelli-Gattinara G.

AIDS. 2007 Nov 30;21(18):2465-72.

PMID:
18025883
8.

Impact of PI and NNRTI HAART-based therapy on oral lesions of Brazilian HIV-infected patients.

Ortega KL, Vale DA, Magalhães MH.

J Oral Pathol Med. 2009 Jul;38(6):489-94. doi: 10.1111/j.1600-0714.2009.00783.x. Epub 2009 Apr 28.

PMID:
19453845
9.

Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.

Friis-Møller N, Weber R, Reiss P, Thiébaut R, Kirk O, d'Arminio Monforte A, Pradier C, Morfeldt L, Mateu S, Law M, El-Sadr W, De Wit S, Sabin CA, Phillips AN, Lundgren JD; DAD study group.

AIDS. 2003 May 23;17(8):1179-93.

PMID:
12819520
10.

Combination antiretroviral therapy without a nucleoside reverse transcriptase inhibitor: experience from 334 patients in three cohorts.

Calmy A, Petoumenos K, Lewden C, Law M, Bocquentin F, Hesse K, Cooper D, Carr A, Bonnet F; Aquitaine Cohort, Australian HIV Observational Database and St Vincent's Hospital Cohort study groups.

HIV Med. 2007 Apr;8(3):171-80.

11.

[HIV infection, antiretroviral therapy, and endothelium].

Hürlimann D, Weber R, Enseleit F, Lüscher TF.

Herz. 2005 Sep;30(6):472-80. Review. German.

PMID:
16170677
12.

Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.

Gatell J, Salmon-Ceron D, Lazzarin A, Van Wijngaerden E, Antunes F, Leen C, Horban A, Wirtz V, Odeshoo L, Van den Dungen M, Gruber C, Ledesma E; SWAN Study Group.

Clin Infect Dis. 2007 Jun 1;44(11):1484-92. Epub 2007 Apr 25.

PMID:
17479947
13.

Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.

Masiá M, Padilla S, Bernal E, Almenar MV, Molina J, Hernández I, Graells ML, Gutiérrez F.

Clin Ther. 2007 Jul;29(7):1448-55.

PMID:
17825696
14.

Incidence of lipodystrophy and metabolic disorders in patients starting non-nucleoside reverse transcriptase inhibitors in Benin.

Zannou DM, Denoeud L, Lacombe K, Amoussou-Guenou D, Bashi J, Akakpo J, Gougounon A, Akondé A, Adé G, Houngbé F, Girard PM.

Antivir Ther. 2009;14(3):371-80.

PMID:
19474471
15.

Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study.

Tsiodras S, Mantzoros C, Hammer S, Samore M.

Arch Intern Med. 2000 Jul 10;160(13):2050-6.

PMID:
10888979
16.
17.

Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study.

Young J, Rickenbach M, Weber R, Furrer H, Bernasconi E, Hirschel B, Tarr PE, Vernazza P, Battegay M, Bucher HC.

Antivir Ther. 2005;10(1):73-81.

PMID:
15751765
18.
19.

Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use.

Kwong GP, Ghani AC, Rode RA, Bartley LM, Cowling BJ, da Silva B, Donnelly CA, van Sighem AI, Cameron DW, Danner SA, de Wolf F, Anderson RM.

AIDS. 2006 Oct 3;20(15):1941-50.

PMID:
16988515
20.

Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy.

Lainka E, Oezbek S, Falck M, Ndagijimana J, Niehues T.

Pediatrics. 2002 Nov;110(5):e56.

PMID:
12415062

Supplemental Content

Support Center